drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy manufactured via SIN lentiviral transduction of CD4/CD8 T cells; single IV dose (1×10^6/kg). Designed to deplete CD19+ B cells and plasmablasts to reduce autoantibody-driven inflammation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered via lentiviral transduction to express an anti-CD19 chimeric antigen receptor that recognizes CD19 on B-lineage cells. Upon engagement, CAR T cells mediate cytotoxic killing (e.g., perforin/granzyme) and depletion of CD19+ B cells and plasmablasts, leading to reduced autoantibody production and attenuation of B cell–driven inflammation.
drug_name
CD19-CAR_Lenti
nct_id_drug_ref
NCT06685042